Free Trial
NASDAQ:CTOR

Citius Oncology (CTOR) Stock Price, News & Analysis

Citius Oncology logo
$1.88 +0.01 (+0.53%)
Closing price 04:00 PM Eastern
Extended Trading
$1.90 +0.02 (+0.80%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Citius Oncology Stock (NASDAQ:CTOR)

Key Stats

Today's Range
$1.80
$1.93
50-Day Range
$1.48
$5.32
52-Week Range
$0.55
$6.19
Volume
146,850 shs
Average Volume
1.23 million shs
Market Capitalization
$147.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
Consensus Rating
Hold

Company Overview

Citius Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
19th Percentile Overall Score

CTOR MarketRank™: 

Citius Oncology scored higher than 19% of companies evaluated by MarketBeat, and ranked 871st out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Citius Oncology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Citius Oncology has received no research coverage in the past 90 days.

  • Read more about Citius Oncology's stock forecast and price target.
  • Price to Book Value per Share Ratio

    Citius Oncology has a P/B Ratio of 2.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for CTOR.
  • Dividend Yield

    Citius Oncology does not currently pay a dividend.

  • Dividend Growth

    Citius Oncology does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CTOR.
  • Search Interest

    Only 3 people have searched for CTOR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Citius Oncology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.57% of the stock of Citius Oncology is held by insiders.

  • Percentage Held by Institutions

    70.52% of the stock of Citius Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Citius Oncology's insider trading history.
Receive CTOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Citius Oncology and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CTOR Stock News Headlines

Citius Oncology Conducts Public Offering of Stock
Why Trump’s “Smart Dollar” could rewrite the rules
MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's latest plans for the dollar – and they're so bold that one central bank chair says we haven't seen anything like it in almost a century. Our Wall Street insider says it's the start of a once-in-a-lifetime investing opportunity, IF you act now.tc pixel
Citius Oncology Beats Fiscal Q3 EPS
See More Headlines

CTOR Stock Analysis - Frequently Asked Questions

Citius Oncology's stock was trading at $1.15 at the beginning of 2025. Since then, CTOR stock has increased by 63.5% and is now trading at $1.88.

Citius Oncology, Inc. (NASDAQ:CTOR) posted its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02.

Top institutional shareholders of Citius Oncology include Jane Street Group LLC (0.14%), Geode Capital Management LLC (0.07%), Arkadios Wealth Advisors (0.01%) and Bank of America Corp DE (0.01%).

Shares of CTOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Oncology investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Advanced Micro Devices (AMD), Broadcom (AVGO), Confluent (CFLT), Genius Sports (GENI) and Intel (INTC).

Company Calendar

Last Earnings
5/14/2025
Today
9/05/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CTOR
Previous Symbol
NASDAQ:CTOR
CIK
1851484
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

High Price Target
$3.00
Low Price Target
$3.00
Potential Upside/Downside
+59.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-51.93%
Return on Assets
-22.17%

Debt

Debt-to-Equity Ratio
0.12
Current Ratio
0.35
Quick Ratio
0.02

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.64 per share
Price / Book
2.94

Miscellaneous

Outstanding Shares
78,370,000
Free Float
74,789,000
Market Cap
$147.34 million
Optionable
N/A
Beta
2.99
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:CTOR) was last updated on 9/5/2025 by MarketBeat.com Staff
From Our Partners